Nov 13, 2025

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

Sajith Wickramasekara, CEO of Benchling, discusses the broken economics of drug development, where high costs and failure rates stifle innovation. He explains how the biotech industry is facing a 'dot com' bust and new competition from China, and argues that AI agents and simulation can provide the solution by making science less artisanal and helping scientists create better molecules through faster, cheaper experiments.

Oct 20, 2025

Introducing Claude for Life Sciences

Anthropic's Jonah Cool and Eric Kauderer-Abrams outline their vision for making Claude an indispensable AI research assistant for scientists. They discuss a multi-faceted strategy that includes enhancing model capabilities for long-horizon tasks, building a rich ecosystem through partnerships with companies like Benchling and 10x Genomics, and applying Claude across the entire R&D lifecycle—from bioinformatics analysis to navigating regulatory submissions.

Oct 20, 2025

How AbbVie accelerates drug discovery with Claude

Sarah Nam, VP of AI Strategy and Partnerships at AbbVie, and Anthropic’s Ivy Weng discuss how AbbVie is transforming pharmaceutical research and development with AI, from reimagining drug discovery and clinical trials to driving enterprise-wide adoption and evaluating strategic partnerships.

Sep 15, 2025

Faster Science, Better Drugs

Erik Torenberg, Patrick Hsu (Arc Institute), and Jorge Conde (a16z) discuss Arc's moonshot to create 'virtual cells' using foundation models to simulate biology. They cover why science is slow, how AI can accelerate drug discovery by predicting cellular perturbations, and the remaining bottlenecks in clinical trials and capital intensity that the biotech industry faces.

Jul 03, 2025

No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

Chai Discovery's co-founders discuss Chai 2, their new generative AI platform for antibody design. It achieves a nearly 20% hit rate from just 20 computational attempts, a 100-fold improvement over previous methods, signaling a shift from drug discovery to drug engineering.

Jun 05, 2025

A quest for a cure: AI drug design with Isomorphic Labs

Experts from Isomorphic Labs discuss how AI, particularly models like AlphaFold3, is revolutionizing drug discovery. They explain the shift from the slow, iterative process of traditional methods to a new era where generative AI can design novel molecules, optimize for multiple biological properties simultaneously, and pave the way for personalized medicine.